Open Forum Infect Dis . Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patient

[tetano]

Open Forum Infect Dis


. 2022 May 26;9(6)fac064.
doi: 10.1093/ofid/ofac064. eCollection 2022 Jun.
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients


M Veronica Dioverti[SUP] 1 [/SUP], David C Gaston[SUP] 2 [/SUP], C Paul Morris[SUP] 2 [/SUP], Carol Ann Huff[SUP] 3 [/SUP], Tania Jain[SUP] 3 [/SUP], Richard Jones[SUP] 3 [/SUP], Viki Anders[SUP] 3 [/SUP], Howard Lederman[SUP] 1 [/SUP], Jacqueline Saunders[SUP] 4 [/SUP], Heba H Mostafa[SUP] 2 [/SUP], Robin K Avery[SUP] 1 [/SUP]



Affiliations

• PMID: 35663288
• PMCID: PMC9154336
• DOI: 10.1093/ofid/ofac064

Abstract

Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

Keywords: B-cell-depleted; monoclonal antibodies; prolonged SARS-CoV-2.